会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 31. 发明授权
    • Antibody conjugates with macrocyclic ligands
    • 抗体结合物与大环配体
    • US5271927A
    • 1993-12-21
    • US33461
    • 1993-03-18
    • David ParkerThomas A. Millican
    • David ParkerThomas A. Millican
    • A61K51/10C07D257/02C07D257/10C07D273/00C07D401/12C07D403/12A61K39/395A61K47/06A61K47/16A61K47/22
    • C07D273/00A61K51/1093C07D257/02C07D257/10C07D401/12C07D403/12A61K2123/00
    • The conjugation of antibodies to a macrocyclic conjugate compound wherein the conjugate compound has the structure (I), wherein R.sup.1 is --(CH.sub.2).sub.p --R.sup.6 --CH.sub.2).sub.q -- where p and q are the same or different and are 0, 1 or 2, and --R.sup.6 -- is --((CH.sub.2).sub.n --, where n is 0 or 1, --NH--, --O--, --S-- or (II), R.sup.1 optionally being alkyl substituted, provided that neither p nor q is 0 unless R.sup.6 is --CH.sub.2 --; R.sup.2 are --CH.sub.2 CH.sub.2 -- or --CH.sub.2 CH.sub.2 CH.sub.2 --, optionally alkyl, alkoxyalkyl or hydroxyalkyl substituted; R.sup.3 are the same or different and are --H, alkyl, hydroxyalkyl, alkoxyalkyl, carboxyalkyl, carboxyalkyl ester, phosphate, sulphonate or phosphonate; R.sup.4 is one of the compounds of formula (III) optionally alkyl substituted, wherein R.sup.7 is --H, alkyl, hydroxyalkyl, or alkoxyalkyl provided that when R.sup.4 is (III d), R.sup.3 is not carboxyalkyl, R.sup.5 is a linker, and Ab is an antibody. The conjugate compound provides for complexes of metals such as Tc, Co, Re, Cu, Au and Ag which are useful reagents for in vivo imaging and therapy.
    • 抗体与大环结合化合物的缀合,其中偶联化合物具有结构(I),其中R 1是 - (CH 2)p -R 6 -CH 2)q-,其中p和q相同或不同,并且是0,1或 2,-R6-为((CH2)n-,其中n为0或1,-NH-,-O - , - S-或(II),R1任选为烷基取代基,条件是p和q 除非R6是-CH2-; R2是-CH2CH2-或-CH2CH2CH2-,任选地烷基,烷氧基烷基或羟烷基取代; R3相同或不同,是-H,烷基,羟基烷基,烷氧基烷基,羧基烷基,羧基烷基酯,磷酸酯 ,磺酸盐或膦酸盐; R4是任选被烷基取代的式(III)化合物之一,其中R 7是-H,烷基,羟基烷基或烷氧基烷基,条件是当R 4是(III d)时,R 3不是羧基烷基,R 5是 接头和Ab是抗体,偶联化合物提供了诸如Tc,Co,Re,Cu,Au和Ag的金属络合物,它们是用于体内成像和治疗的有用试剂。
    • 37. 发明授权
    • Power relay
    • 电源继电器
    • US07548146B2
    • 2009-06-16
    • US11616584
    • 2006-12-27
    • David ParkerKurt T. Zarbock
    • David ParkerKurt T. Zarbock
    • H01H67/02
    • H01F7/13H01H11/0012H01H50/14H01H50/20H01H50/546
    • A first aspect of the invention includes a power relay assembly having a motor assembly and actuator assembly disposed in a housing. The actuator assembly includes at least one bridge assembly having one or more contacts arranged to provide selective electrical connections. The actuator assembly is attached to an armature of the motor assembly. The armature is arranged and disposed to drive the actuator assembly. The motor assembly includes an electromagnetic coil assembly disposed around at least a portion of the armature. A magnetic pole piece is configured adjacent to an end of the coil assembly. The pole piece includes an armature seat configured to attract and receive the armature when the coil assembly is magnetized. The armature seat has a taper configured to provide a substantially constant attractive force along the stroke length.
    • 本发明的第一方面包括功率继电器组件,其具有设置在壳体中的马达组件和致动器组件。 致动器组件包括至少一个桥接组件,其具有布置成提供选择性电连接的一个或多个触点。 致动器组件附接到电动机组件的电枢。 电枢布置和布置成驱动致动器组件。 马达组件包括围绕衔铁的至少一部分设置的电磁线圈组件。 磁极片构造成与线圈组件的端部相邻。 极片包括电枢座,其构造成当线圈组件被磁化时吸引和接收电枢。 衔铁座具有锥形,其被构造成沿着行程长度提供基本恒定的吸引力。
    • 38. 发明申请
    • PACKET PROCESSING SYSTEM ARCHITECTURE AND METHOD
    • 分组处理系统架构和方法
    • US20080008099A1
    • 2008-01-10
    • US11860045
    • 2007-09-24
    • David ParkerErik SwensonMichael YipChristopher Young
    • David ParkerErik SwensonMichael YipChristopher Young
    • H04L12/56
    • H04L47/2441H04L47/10H04L47/2433H04L47/36H04L49/901
    • A packet processing system architecture and method are provided. According to a first aspect of the invention, a plurality of quality of service indicators are provided for a packet, each with an assigned priority, and a configurable priority resolution scheme is utilized to select one of the quality of service indicators for assigning to the packet. According to a second aspect of the invention, wide data paths are utilized in selected areas of the system, while avoiding universal utilization of the wide data paths in the system. According to a third aspect of the invention, one or more stacks are utilized to facilitate packet processing. According to a fourth aspect of the invention, a packet size determiner is allocated to a packet from a pool of packet size determiners, and is returned to the pool upon or after determining the size of the packet. According to a fifth aspect of the invention, a packet is buffered upon or after ingress thereof to the system, and a packet for egress from the system assembled from new or modified packet data and unmodified packet data as retrieved directly from the buffer. According to a sixth aspect of the invention, a system for preventing re-ordering of packets in a packet processing system is provided. A seventh aspect of the invention involves any combination of one or more of the foregoing.
    • 提供了一种分组处理系统架构和方法。 根据本发明的第一方面,为分组提供多个服务质量指示符,每个具有分配的优先级,并且使用可配置的优先级分辨率方案来选择用于分配给分组的服务质量指示符之一 。 根据本发明的第二方面,在系统的选定区域中使用宽数据路径,同时避免系统中广泛的数据路径的普遍利用。 根据本发明的第三方面,使用一个或多个堆栈来促进分组处理。 根据本发明的第四方面,分组大小确定器从分组大小确定器池分配给分组,并且在确定分组的大小之后或之后返回到分组。 根据本发明的第五方面,一个数据包在其进入系统之后或之后被缓存,并且一个用于从新系统或修改的分组数据组装的用于出口的分组以及从缓冲器直接获取的未修改的分组数据。 根据本发明的第六方面,提供一种用于防止分组处理系统中的分组重新排序的系统。 本发明的第七方面涉及上述中的一种或多种的任意组合。
    • 39. 发明申请
    • Assay
    • 测定
    • US20070292839A1
    • 2007-12-20
    • US10577358
    • 2004-11-01
    • David Parker
    • David Parker
    • C12Q1/70G01N33/556
    • G01N33/6854G01N2469/20
    • The invention relates to a method of determining the amount or presence of antibodies to an immunogen in a blood sample comprising at least the steps of detecting the amount or presence of plasma antibodies or parts thereof and lymphocyte antibodies or parts thereof in said sample, wherein said plasma and lymphocyte antibodies are detected together or in separate assays and determination of their combined amount or presence determines the amount or presence of antibodies to said immunogen. Uses of the method in high throughput screening, screening of blood bank samples and in diagnosis are also provided.
    • 本发明涉及一种确定血液样品中免疫原抗体的量或存在的方法,包括至少检测所述样品中血浆抗体或其部分的量或存在的量以及淋巴细胞抗体或其部分的步骤,其中所述 血浆和淋巴细胞抗体一起检测或在单独的测定中检测,并且其组合量或存在的测定决定了抗体对所述免疫原的量或存在。 还提供了在高通量筛选,血库样本筛选和诊断中使用该方法。